← All trials
NCT01667536
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 1, 2012
- Primary completion
- Dec 1, 2013
- Completion date
- Dec 1, 2013
- First posted
- —
- Last posted
- —
- Enrollment
- 105
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- Molecular Insight PharmaceuticalsLead sponsor
- Mayo ClinicOverall official - principal investigator
- University of WashingtonOverall official - principal investigator
- Duke UniversityOverall official - principal investigator
- University of WisconsinOverall official - principal investigator
- Medical University of South CarolinaOverall official - principal investigator
- University of Texas at HoustonOverall official - principal investigator
- City Clinical Hospital # 57Overall official - principal investigator
- Research Institute of Oncology n.a. Professor N.N. Petrov under the Federal Agency for Healthcare and Social DevelopmentOverall official - principal investigator
- Thomayer's HospitalOverall official - principal investigator
- Charles UniversityOverall official - principal investigator
- Cornell UniversityOverall official - principal investigator
- Palacky UniversityOverall official - principal investigator
- University of PilsenOverall official - principal investigator
- Vita-Salute University of Milano. ItalyOverall official - principal investigator
- Moscow Oncology Research InstituteOverall official - principal investigator
- St. Petersburg State Public Medical InstitutionOverall official - principal investigator
- Government of RussiaOverall official - principal investigator
- Radboud UniversityOverall official - principal investigator
- Thomas Jefferson UniversityOverall official - principal investigator
- Peterfy Sandor Street HospitalOverall official - principal investigator
- City of Hope National Medical CenterOverall official - principal investigator
- University of RochesterOverall official - principal investigator
- Wroclaw Medical UniversityOverall official - principal investigator
- All-Russia Centre for Urgent Care and Radiation MedicineOverall official - principal investigator
- Bajcsy-Zsilinszky HospitalOverall official - principal investigator
- Jahn Ferenc South Pest HospitalOverall official - principal investigator
- Katholieke Universiteit LeuvenOverall official - principal investigator
- Russian Academy of Medical SciencesOverall official - principal investigator
- University of TurinOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.